Stroke
Conference Coverage
Stroke endovascular therapy: The more you do, the better you do
HONOLULU – Centers performing more endovascular thrombectomies produced better patient outcomes.
Conference Coverage
Noncardiac surgery has 7% covert stroke rate in elderly
HONOLULU – Covert strokes were linked with a doubled rate of cognitive decline in older patients after noncardiac surgery.
From the Journals
Hormone therapy in transgender individuals may up risk of CV events
“It may be helpful to reduce risk factors by stopping smoking, exercising, eating a healthy diet, and losing weight, if needed before starting...
From the Journals
ICYMI: Andexanet alfa reduces anti–factor Xa activity from apixaban, rivaroxaban
Reductions were similar for those receiving apixaban and rivaroxaban.
Video
Minimally invasive ICH lysis safely helps when clot adequately shrinks
HONOLULU – The primary endpoint from the phase 3 MISTIE III trial was neutral, apparently because clot lysis often fell short.
Conference Coverage
Deferoxamine does not improve 90-day outcomes after ICH
HONOLULU – The drug is safe, and data suggest that it could improve 180-day outcomes.
Conference Coverage
Vaccination and antiviral treatment do not affect stroke risk following shingles
HONOLULU – Preventing shingles through vaccination might be the best method for preventing shingles-associated acute...
Conference Coverage
Most U.S. tPA-eligible stroke patients now get treated within an hour
The most recent phase of the Target: Stroke program met its tPA delivery-time target in September 2018.
Conference Coverage
Cilostazol plus aspirin or clopidogrel reduces the risk of recurrent stroke
HONOLULU – Dual therapy with cilostazol and aspirin or clopidogrel did not increase the risk of serious bleeding.
Conference Coverage
Intensive insulin added no benefit for hyperglycemia after ischemic stroke
Results from a large RCT showed intensive and standard insulin regimens produced similar clinical outcomes after an acute ischemic stroke.
From the Journals
Statins cut vascular events in elderly patients
Analysis challenges current practice of discontinuation after age 75 years.